Volastra Therapeutics Expands Clinical Development Program Following Encouraging KIF18A Inhibitor Data and Appoints New Chief Medical Officer to Lead Clinical Strat…

Volastra Therapeutics, a clinical-stage biotechnology company pioneering first-in-class therapies targeting chromosomal ...
Seeking Alpha

Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology Transcript

Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...
Business Wire

Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call

Basket Trials Evaluating Tazemetostat Combinations for Multiple New Heme and Solid Tumor Cancers to be Initiated in Second Half 2021 “The recent accelerated approvals of TAZVERIK in Epithelioid ...
Detroit Free Press

NanoViricides Dual Track Clinical Strategy Explained by a Research Report – Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...

Tubulis Appoints Charles Fuchs, MD as Chief Medical Officer to Lead Clinical Strategy and Pipeline Development

Tubulis today announced the appointment of Charles Fuchs, MD, as Chief Medical Officer (CMO). Dr. Fuchs is an internationally ...
Labiotech.eu

From science to scale: building biotech companies via milestone leadership

Explore how leadership in biotech drives success through a milestone approach, aligning teams and culture from science to ...
Morningstar

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains ...